The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity

Hui Xing; Yang Wang; Bo Qu; Qiang Wei; Cuihua Li; Chao Pan; Hui Li

doi:10.1016/j.tranon.2023.101619

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity

Transl Oncol. 2023 Feb:28:101619. doi: 10.1016/j.tranon.2023.101619. Epub 2023 Jan 7.

Authors

Hui Xing¹, Yang Wang², Bo Qu¹, Qiang Wei², Cuihua Li¹, Chao Pan¹, Hui Li³

Affiliations

¹ Digestive Department, Second affiliated hospital of Harbin Medical University, No.246 Xuefu Road, Harbin 150086, China.
² Suzhou Suncadia Biopharmaceuticals Co., Ltd., Suzhou 215000, China.
³ Digestive Department, Second affiliated hospital of Harbin Medical University, No.246 Xuefu Road, Harbin 150086, China. Electronic address: melanielihui@126.com.

Abstract

ICI-related hepatotoxicity (IRH) is becoming more and more common as immune checkpoint inhibitors (ICIs) have begun to be increasingly approved and used in combination with other anti-tumor drugs worldwide. Steroids are the first choice for the treatment of IRH, but the subsequent optimal treatment algorithm remains unclear if the disease progresses to steroid-refractory IRH. Therefore, in this paper we reviewed all the pertinent literature on steroid-refractory IRH to the greatest extent possible in an attempt to provide information on which to base an update of the treatment algorithm for steroid-refractory IRH.

Keywords: Cholangitis; Drug-resistance; Hepatitis; Hepatotoxicity; Immune checkpoint inhibitors; Steroid.

Publication types

Review